Polyphron
Polyphron trains AI models to manufacture and simulate living human tissue. Its Tissue Foundry grows donor-diverse micro-tissue from stem cells, and its Tissue World Model predicts how that tissue responds to genetic, chemical and environmental changes. The aim is to give AI-driven drug development a verification layer, for example by predicting cardiac or liver toxicity before a drug reaches the clinic. Cardiac tissue is in production, and liver is planned for 2026. In September 2026 the company announced a $20M seed round led by Quiet Capital, with Gradient, Haystack and Compound participating. It was founded by CEO Matthew Osman, CSO Fabio Boniolo and Chief AI Scientist Vinh Q. Tran.
Funding
Every round, secondary, debt facility or acquisition involving Polyphron that AI Lounge tracks, newest first. Latest: Seed on Sep 17, 2026.
Timeline · 2
In the news
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in